Texas A&M Licenses Technology To XOMA

Texas A&M University and biopharmaceuticals firm XOMA, Ltd. said this week that the school has signed a memorandum of understanding to work together on antibodies and protein-based therapeutics for both human and veterinary applications. Financial details of the agreement were not disclosed. According to Texas A&M and XOMA, the MOU covers programs for advancing healthcare research and technologies through the development of new methods, standards and intellectual properties. Texas A&M explained that the result in "a significant gain" in monoclonal antibody research and production in the State of Texas.